J.B. Chemicals Announces Q2 Results - September 2006

J.B. Chemicals & Pharmaceuticals Ltd. Announces a Licensing Agreement with Gilead Sciences Inc. for Manufacturing and Distribution of a Generic Version of an Anti-Viral Patented drug in 95 countries

J. B. CHEMICALS reports increase in Net Sales and PAT for Q1 ended June 30, 2006.

J. B. Chemicals & Pharmaceuticals Limited Announces Audited Financial Results for FY 2005-06.

US FDA ACCEPTS JBCPL’s ELECTRONIC USDMF FILING FOR DICLOFENAC DIETHYLAMINE

J. B. Chemicals announces encouraging Q3 results.

Chairman’s Speech

J. B. Chemicals enters into Product Development Agreement with Taro Pharmaceutical Industries Ltd.

J. B. CHEMICALS TO SET-UP WHOLLY OWNED SUBSIDIARY IN RUSSIA

JBCPL Makes it to FORBES Asia Pacific 200 List for “Best Under a Billion” for second year in a row

J.B. CHEMICALS ANNOUNCES Q2 RESULTS

JBCPL receives US FDA approval to market Fluconazole tablets in the US market.

Clarification on news 'JB Chem to buy Russian Firm'

J. B. CHEMICALS reports increase in Net Sales and PAT for Q1 ended June 30, 2005.

'Doktor Mom' brand of J. B. Chemicals once again does India proud in the international market

Ranbaxy to market Doktor Mom Herbal brand range of JBCPL, in Romania

JBCPL strengthens/expands board with two additional Directors

Chairman's Letter

JBCPL Announces Audited Financial Results for FY 2004-05.

JBCPL forays into Kangaroo (Australian) Country

JBCPL's Doktor Mom is Most Trusted European Brand 2005

TGA Australia approves JBCPL's tablets facility at Panoli.

Renowned Intl Cardiologist Dr. Philip A. Poole Wilson Shares Findings Of Trials on Anti-Anginal Drug

JBCPL reports increase in turnover and Net Profit for the Q3 ended December 31, 2004

US FDA accepts JBCPL's DMF API for Ciprofloxacin Hydrochloride

JBCPL launches Magnilek, a MRI CONTRAST media, expanding its High-Tech Diagnostic Product Range

JBCPL To Foray Into Biotechnology

JBCPL announces Q2 RESULTS

JBCPL appoints Mr. Jay Mehta as Vice President, R&D

JBCPL announces maiden US FDA approval to market ciprofloxacin tablets in the US market

MHRA, UK approves JBCPL's Tablets Manufacturing Facility at Panoli.

JBCPL reports increase in Net Sales and PAT for Q1 ended June 30, 2004.

JBCPL Strengthens Management Team to Enhance its International Business

Chairman's Speech - AGM

JBCPL Announces Year End Audited Financial Results

JBCPL reports increase in turnover and Net Profit for the Q3 ended December 31, 2003.

USFDA approves JBCPL's API Facility at Panoli.

J. B. Chemicals Panoli Manufacturing facilities gets Columbian FDA nod.

J. B. Chemicals Launches Cefjoy and Zudo for treatment of infections and health improvement.

J.B.Chemicals to set-up new Strategic Business Units (SBU's) to focus on Neuro-psychiatry and Oncology.

J.B. Chemicals Q2 Net Profit up 17.23%, to pay 45% Interim Dividend

Lannett Co. Inc., USA to Market and Distribute J. B. Chemical & Pharmaceuticals Ltd.'s Ciprofloxacin in USA

J. B. Chemicals a.. bets big on R&D b.. To set-up world class R&D Centre in Maharashtra, at an expected cost of Rs.40 Cr.

J. B. Chemical & Pharmaceuticals Ltd. becomes the first Indian Company to receive permission to market Rantac CD (once a day) formulations

J.B.Chemicals & Pharmaceuticals Ltd. First Quarter Net Profit up 9% to Rs.9.25 Cr.

Chairman's Speech at AGM 2002-03.

J.B. Chemicals & Pharmaceuticals plans New Products for Domestic & Export Markets.To Enter Diabeto, Respiratory, Oncology Segments.To pay 80% Dividend.

EU Certification Renewal for J. B. Chemicals & Pharmaceuticals Ltd.

J. B. Chemicals enters into strategic alliance with Arrow group, Canada

J. B. Chemical & Pharmaceuticals Ltd. Announces US FDA Acceptance of ANDA Filing for Ciprofloxacin

J. B. Chemicals & Pharmaceuticals Limited Turnover Up 6% PAT Up 16% Recommends 80% Dividend

Mr. Siba Prasad Maitra joins as Senior Marketing Director, J. B. Chemicals

J.B. Chem's 'Doktor Mom' is Most Trusted European Brand 2003 Receives Award for Third Successive Year.

J.B.Chemicals & Pharmaceuticals Ltd. announces Filing of first ANDA with the US FDA for approval to market generic drugs in the United States and Plans additional filings during 2003; looks for revenue from generic business during 2004.